Toboroz
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
NCT07621614· 2. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
NCT07022678· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
NCT07466316· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
NCT06647953· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817· 2. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
NCT06410209· 2. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Fut, nem toboroz
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· 3. fázis· Children's Oncology Group· Forrás
Toboroz
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
NCT05705531· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241· 1/2. fázis· PedAL BCU, LLC· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368· 2. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318· 2. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Toboroz
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Fut, nem toboroz
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
NCT03350828· Nicole Hamblett· Forrás
Fut, nem toboroz
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579· 2. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03213704· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628· 2. fázis· Children's Oncology Group· Forrás
Toboroz
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· 3. fázis· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Fut, nem toboroz
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521493· 3. fázis· Children's Oncology Group· Forrás
Toboroz
Project: Every Child for Younger Patients With Cancer
NCT02402244· Children's Oncology Group· Forrás
Contact: Jeffrey H. Schwartz (principal investigator)
Fut, nem toboroz
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
NCT02339740· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02166463· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02306161· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02112916· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967· 3. fázis· Children's Oncology Group· Forrás
Toboroz
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749· Children's Oncology Group· Forrás